Written and maintained by CASRAI Editorial Board
Published
On this page
Short answer: SV40 (simian virus 40) is a small DNA virus of Asian macaques that contaminated some polio vaccine lots made between 1955 and 1963. No vaccine used in the U.S. since the early 1960s has been contaminated. In laboratories its large T antigen is a widely used tool, and handling rules are set by the institution’s biosafety committee.
General information for researchers and lab and clinic staff, not medical advice.
Definition and scope: what is SV40 (simian virus 40)?
SV40 belongs to the Polyomaviridae, the family that also includes the human viruses JC and BK. It is a small, nonenveloped, icosahedral DNA virus with a circular genome of about 5 kilobases. Its natural host is the Asian macaque (rhesus monkey), where it causes persistent infection, often in the kidney (Clinical Microbiology Reviews, 2004).
Where is SV40 found?
In nature, SV40 is found in macaques. It reached humans mainly through contaminated vaccines: the virus was present in monkey kidney cells used to grow vaccine viruses, and was identified in 1960 by Hilleman and Eddy (CHOP Vaccine Education Center). Antibodies to SV40 have also been reported in people who were never vaccinated, and the 2004 review states that the mode of transmission among humans is unknown. Reported antibody prevalence in general populations ranged from about 2 to 20 percent across studies, and 41 to 55 percent in laboratory workers handling infected monkeys.
Do all vaccines contain SV40?
No. SV40 is not an ingredient of current vaccines. It was an accidental contaminant of some vaccines in a specific period. CHOP’s Vaccine Education Center states that no vaccines used in the U.S. since the early 1960s have been contaminated, and notes that some other countries took longer.
When did they stop using SV40-contaminated vaccine?
After the virus was identified in 1960, the U.S. required testing in 1961. Previously approved inactivated polio vaccine lots were still used until early 1963. The table below lists the exposures CHOP describes.
| Exposure | Period | People and extent (CHOP) |
|---|---|---|
| Salk inactivated polio vaccine (IPV) | 1955-1963 | About 98 million recipients; 10 to 30 percent of doses contaminated |
| Inactivated adenovirus vaccine, military recruits | 1961-1965 | About 100,000 recipients |
| Sabin oral polio vaccine trials | 1959-1961 | About 10,000 recipients; no immune response to the virus detected |
| Experimental live RSV vaccine (never licensed) | Not stated | About 100 adults |
The 2004 review estimates that up to 30 million people in the U.S. were exposed between 1955 and 1963.
What does SV40 do to humans?
The evidence is unsettled. In animals, SV40 causes tumors, including brain, lung-lining, bone and lymph node tumors. In humans, SV40 DNA has sometimes been found in mesothelioma, osteosarcoma, non-Hodgkin lymphoma and some brain tumors, but causal evidence is inconsistent. A 2004 meta-analysis of 1,793 cancer patients reported excess SV40 in brain and bone cancers, mesothelioma and lymphomas and a possible etiologic role, a conclusion that remains disputed. Epidemiological studies cited by CHOP found no increased cancer risk among people who received polio vaccine in 1955-1963.
| Claim | Status in the sources |
|---|---|
| SV40 contaminated some polio vaccine lots, 1955-1963 | Established (CHOP) |
| Vaccines used in the U.S. since the early 1960s are contaminated | No (CHOP) |
| SV40 causes tumors in animals | Established (CHOP) |
| SV40 DNA is present in some human tumors | Reported; causal role inconsistent (CHOP; 2004 review) |
| Polio vaccine recipients had higher cancer rates | Not found in epidemiology (CHOP) |
| Route of human-to-human transmission | Unknown (2004 review) |
SV40 in the laboratory: large T antigen
The large T antigen is SV40’s main transforming protein. It is needed to start viral DNA synthesis, pushes cells into S phase, and binds the tumor suppressors p53 and pRb (2004 review). See HEK 293 cells for a widely used human cell line, plasmid design for how promoters and markers are chosen, and Addgene for plasmid sourcing.
Stanford Environmental Health and Safety’s page on recombinant viral vector biosafety levels states that SV40 T antigen-containing cells should not be considered more hazardous than the intact virus, and excludes SV40 T antigen from its definition of oncogene. It does not assign a biosafety level to SV40, and it adds that a cautionary note might be in order given the possible causative role in some human cancers. In practice, the containment level and work practices for SV40 and T-antigen cell lines are set by your institution’s Institutional Biosafety Committee within the framework of the biosafety level system. Confirm the requirement for your protocol with your biosafety office before work begins.
Common misunderstandings
- “SV40 is in vaccines today.” Not in vaccines used in the U.S. since the early 1960s (CHOP).
- “SV40 is proven to cause human cancer.” Human evidence is inconsistent and disputed; animal tumor evidence is not in dispute.
- “SV40 is a human virus.” Its natural host is the macaque; human infection is documented but its transmission route is unknown.
FAQ
Do all vaccines contain SV40?
No. It was a contaminant of some vaccines between 1955 and 1963 and is not an ingredient of current vaccines.
What does SV40 do to humans?
Whether it causes human disease is unsettled. It causes tumors in animals; in humans, its DNA is sometimes found in certain tumors, but causation has not been established and epidemiology of vaccine recipients showed no increased cancer risk.
When did they stop using SV40?
Testing was required in the U.S. from 1961 and previously approved lots were used until early 1963. Some other countries took longer.
Where is SV40 found?
In Asian macaques naturally, and historically in monkey kidney cell cultures used to make vaccines. Antibodies have been reported at low rates in general human populations.
Sources
- Children’s Hospital of Philadelphia Vaccine Education Center, Vaccine Ingredients: SV40 (read 2026-11-07).
- Clinical Microbiology Reviews (2004), Emergent human pathogen simian virus 40 and its role in cancer, PubMed 15258090 (read 2026-11-07).
- Stanford Environmental Health and Safety, Recombinant Viral Vector Biosafety Levels (read 2026-11-07).







